What’s going on in the world of vasculitis…?
An additional analysis from the MANDARA study shows that steroid-free remission is possible for a subset of patients with EGPA. Biologic therapies such as benralizumab and mepolizumab can support this goal, with benralizumab showing somewhat better outcomes in this specific context.
In a recent article in Rheumatology (Oxford) the Canadian vasculitis experts Christian Pagnoux and Arielle Mendel reflected on the launch of the new BSR Guidelines for the management of AAV.
The authors are welcoming the new 2025 British Society for Rheumatology (BSR) guidelines while emphasizing why doctors should read ALL available guidelines, not just one.
Real world experience A recently published study in Clinical and Experimental Rheumatology offers new real-world data from the University of
The National Institute for Health and Care Excellence (NICE) has officially recommended benralizumab (Fasenra) as a new treatment option for adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
The two-year MANDARA study found benralizumab and mepolizumab equally effective for eosinophilic granulomatosis with polyangiitis (EGPA). About two-thirds of patients
Today, May 15th, is International Vasculitis Day. The entire month of May is dedicated to raising awareness about vasculitis, culminating